Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for LifeStance Health (LFST) over the last 6 years, with Q3 2025 value amounting to $18.3 million.

  • LifeStance Health's Share-based Compensation rose 2283.99% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 840.32%. This contributed to the annual value of $76.2 million for FY2024, which is 2335.9% down from last year.
  • As of Q3 2025, LifeStance Health's Share-based Compensation stood at $18.3 million, which was up 2283.99% from $21.1 million recorded in Q2 2025.
  • In the past 5 years, LifeStance Health's Share-based Compensation ranged from a high of $108.6 million in Q4 2021 and a low of $605000.0 during Q1 2021
  • Over the past 5 years, LifeStance Health's median Share-based Compensation value was $21.5 million (recorded in 2023), while the average stood at $31.2 million.
  • Examining YoY changes over the last 5 years, LifeStance Health's Share-based Compensation showed a top increase of 979338.84% in 2022 and a maximum decrease of 6760.1% in 2022.
  • Over the past 5 years, LifeStance Health's Share-based Compensation (Quarter) stood at $108.6 million in 2021, then crashed by 67.6% to $35.2 million in 2022, then plummeted by 40.56% to $20.9 million in 2023, then decreased by 22.82% to $16.1 million in 2024, then rose by 13.32% to $18.3 million in 2025.
  • Its Share-based Compensation was $18.3 million in Q3 2025, compared to $21.1 million in Q2 2025 and $18.6 million in Q1 2025.